Candidiasis, caused by various Candida species, is a fungal infection that poses a significant challenge in healthcare settings worldwide. Among these species, Candida albicans is the most prevalent opportunistic fungal pathogen, commonly found on human skin and mucous membranes. Our company excels in the field of candidiasis by offering comprehensive one-stop services tailored to the needs of researchers and scientists working in this domain.
Overview of Candidiasis
The prevalence of candidemia cases is estimated to be approximately 10 per 100,000 people, resulting in about 25,000 infections yearly. Candida albicans is the primary cause of infections among Candida species, followed by Candida glabrata, Candida parapsilosis, Candida tropicalis, and Candida krusei. The manifestations of candidiasis can affect various parts of the body, encompassing the skin, mucous membranes, and internal organs. The severity of symptoms can vary from mild to severe depending on the location and extent of the infection.
Fig.1 A schematic diagram showing experimental Candida vaccines. (Sahu, S. R., et al., 2022)
Pathogenesis of Candidiasis
The pathogenesis of candidiasis involves a multifaceted interplay between the host immune response and the virulence factors produced by the fungus. Candida species possess the ability to adhere to host tissues and secrete enzymes that aid in invasion. Moreover, they exhibit the capacity to switch between different morphological forms, facilitating adaptation to diverse host environments. Factors such as immune status, underlying health conditions, and medication use can all influence the progression and severity of candidiasis.
Fig.2 Skin immunity against C. albicans Infection. (Lu, H., et al., 2023)
Vaccine Development for Candidiasis
| Vaccine category |
Name |
Description |
Research Phase |
| Live-attenuated vaccines |
tet-NRG1 |
Filamentation-repressible C. albicans strain tet-NRG1 |
Preclinical research |
| Inactivated vaccines |
HKY |
heat-killed S. cerevisiae yeast (HKY) |
Preclinical research |
| Conjugate |
Lam-CRM197 |
A laminarin conjugated with diphtheria toxoid (CRM197) |
Preclinical research |
| Recombinant |
NDV-3 |
Recombinant N-terminus of Als3p plus alum adjuvant |
Phase I/II trials |
| PEV7 |
A truncated Sap2p embedded into the bilipid layer of an influenza virosomes |
Phase I trials |
| Peptide |
Mimotope-Fba conjugate vaccines |
Fba peptide (14-mer) conjugated with each one of five peptide mimotopes from Met6 (PS2, PS31, PS28, PS55, and PS76) |
Preclinical research |
| DNA vaccines |
Hsp90-CA |
Hsp90-CA-encoding DNA vaccine |
Preclinical research |
Therapeutic Development for Candidiasis
| Name |
Mechanism of Action |
Target |
Research Phase |
| Ibrexafungerp |
A new oral glucan synthase inhibitor |
Glucan synthase |
Phase III trials |
| APX001 |
APX001 is a potent inhibitor of fungal Gwt1, has broad-spectrum antifungal activity against Candida species |
Gwt1 |
Phase II trials |
| Khafrefungin |
An antifungal agent that inhibits inositol phosphorylceramide (IPC) synthase |
IPC synthase |
Preclinical research |
| CMLD013075 |
A highly selective fungal Hsp90 inhibitor |
Hsp90 |
Preclinical research |
| MGCD290 |
Novel Hos2 inhibitor |
Hos2 |
Phase II trials |
Our Services
Our dedicated team of specialists is committed to delivering tailored assistance and direction, supporting researchers throughout all phases of their endeavors. The centralized hub of our infectious disease model, vaccine, and therapeutic development platforms serves as a one-stop destination where researchers can access all essential resources and services, streamlining processes.
Featured Services of Candidiasis
Infectious Disease Models
- Mouse model of Candida albicans systemic / gastrointestinal / vaginal infection
- Toll-deficient Drosophila melanogaster model
- Caenorhabditis elegans intestinal infection model
- Others
Why Choose Us
By consolidating resources and expertise, we empower researchers to focus on their scientific inquiries and drive innovation in the study of candidiasis, ultimately advancing our collective understanding of this important fungal infection.
If you are interested in our service, we encourage you to contact us for further information tailored to your specific research needs.
References
- Sahu, Satya Ranjan et al. "Vaccines against candidiasis: Status, challenges and emerging opportunity." Frontiers in cellular and infection microbiology 12 (2022): 1002406.
- Lu, Hui et al. "Candidiasis: From cutaneous to systemic, new perspectives of potential targets and therapeutic strategies." Advanced drug delivery reviews 199 (2023): 114960.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
